SynthesisCancer medicine2024
Cardiovascular mortality in people with cancer compared to the general population: A systematic review and meta-analysis.
Synthesis in Cancer medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- A Systematic Review of Cardiovascular Health Among Cancer Survivors.International journal of environmental research and public health · 2025Pooled it
- Cardiovascular mortality in people with cancer compared to the general population: A systematic review and meta-analysis.Cancer medicine · 2024Pooled it
- Long-term outcomes of transcatheter mitral valve repair in patients with cancer: a systematic review and meta-analysis.GeroScience · 2026Article
- Genetic and Molecular Determinants of Cancer Therapy-Related Cardiovascular Toxicity.Cardiovascular toxicology · 2026Review
- Assessment of Physical Activity Engagement and Promotion Among Cancer Survivors in Cardio-Oncology Care: Qualitative Study.JMIR cancer · 2026Article
- Circulating Biomarkers in Cardio-Oncology: Prediction and Prognostication.Current cardiology reports · 2026Review
- Subsequent malignant neoplasm among cancer survivors in the United States.Journal of cancer survivorship : research and practice · 2026Article
- Review
- Impact of low serum albumin levels on cardiovascular deaths in cancer survivors with heart failure.Heart and vessels · 2026Article
- Article
- Temporal Trends in Cause-Specific Cardiovascular Disease Mortality Following Cancer Diagnosis.Cancer medicine · 2026Article
- Heterogeneity in proportional cardiovascular co-listing on cancer death certificates in the United States: a national multiple cause-of-death analysis, 1999-2020.Cardio-oncology (London, England) · 2026Article
- Prognostic Impact of Cancer in Patients Hospitalized for Acute Myocardial Infarction: A Population-Based Cohort Study.Journal of clinical medicine · 2026Article
- Immune checkpoint inhibitor-induced myocarditis is dependent on CD8 T cell-derived TNF and TNFR2 signaling.The Journal of experimental medicine · 2026Article
- Temporal trends in myocardial ischemia risk estimated from 12-lead electrocardiograms using deep learning in individuals with suspected cancer during health checkups.Cardio-oncology (London, England) · 2026Article
- Cardiovascular Mortality Risk After Cancer Diagnosis by County-Level Characteristics in the United States 2000-2021.Cancer medicine · 2026Article
- Trends and future projections of cancer prevalence in patients with cardiovascular admissions.European heart journal open · 2026Article
- Coronary artery calcification burden in cancer vs. non-cancer populations: a systematic review and meta-analysis.Cardio-oncology (London, England) · 2026Article
- Treatment of left ventricular dysfunction during cancer therapy: a comprehensive review.Drugs in context · 2026Review
- Cardiovascular risk stratification in inflammatory-driven conditions: how far have we come?Frontiers in cardiovascular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCardiovascular disease (CVD) is the leading cause of non-cancer death in cancer survivors, but the risk of CVD varies between cancers.
objectivesTo synthesise available evidence on patterns and magnitude of CVD mortality risk.
methodsA systematic search of Medline (OVID), CINAHL and Scopus databases from 01-January-2000 to 16-July-2023 of studies of people with cancer, reporting CVD mortality in cancer population compared with a reference population (e.g. general population) as standardised mortality ratios (SMR). Meta-analysis of SMRs across cancer and CVD types were pooled using a random-effects model to allow for heterogeneity of the true effect size across studies.
resultsWe identified 136 studies from 16 countries. Sample sizes ranged from 157 to 7,529,481. The majority (n = 98; 72%) were conducted in the United States, followed by Europe (n = 22; 16%). The most common cancers studied were gastrointestinal (n = 34 studies), haematological (n = 31) and breast (n = 29). A total of 876 CVD SMRs were extracted across diverse CVD conditions. Of those, the majority (535; 61%) indicated an increased risk of CVD death (SMR >1), 109 (12%) a lower risk of CVD death (SMR <1) and 232 (27%) an equivalent risk (95% CI of SMR included 1) compared to the general population. The meta-analysis of all reported SMRs showed an increased risk of CVD death (SMR = 1.55, 95% CI = 1.40-1.72) in cancer survivors compared with the general population. The SMR varied between CVD conditions and ranged from 1.36 (95% CI = 1.29-1.44) for heart diseases to 1.56 (95% CI = 1.39-1.76) for cerebrovascular diseases. SMR varied across cancer types, ranging from 1.14 (95% CI = 1.04-1.25) for testicular/germ cell tumours to 2.82 (95% CI = 2.20-3.63) for brain/central nervous system tumours.
conclusionsCancer survivors are at increased risk of premature CVD mortality compared to the general population, but the risk varies by cancer type and CVD. Future research should focus on understanding mechanisms behind the increased CVD risk to develop appropriate interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.